Pulmonary arterial hypertension in systemic sclerosis

Area of Science:

• Cardiology
• Rheumatology
• Pulmonology

Background:

• Pulmonary arterial hypertension (PAH) is a severe complication of systemic sclerosis (SSc), leading to increased pulmonary vascular resistance and right heart failure.
• PAH is a common and life-threatening condition in connective tissue diseases, particularly SSc, requiring prompt and effective treatment.

Purpose of the Study:

• To review the current understanding of PAH in SSc, including epidemiology, pathophysiology, and diagnostic advancements.
• To discuss novel therapeutic approaches for SSc-PAH based on recent research and clinical practice.

Main Methods:

• Review of large-scale patient cohorts (e.g., EUSTAR) for SSc epidemiology.
• Analysis of current knowledge on PAH pathophysiology.
• Evaluation of advances in cardiopulmonary diagnostic techniques.

Main Results:

• Emerging data from large cohorts have enhanced understanding of SSc epidemiology.
• Advances in diagnostics aid in earlier and more accurate identification of PAH.
• Novel treatments, including endothelin receptor antagonists and PDE-5 inhibitors, are now in clinical use.

Conclusions:

• PAH in SSc is a complex and serious condition requiring timely intervention.
• Recent advances in understanding, diagnosis, and treatment offer improved long-term outcomes for SSc-PAH patients.
• Ongoing research continues to explore new therapeutic strategies to further enhance patient outcomes.